The Association of 340B Program Drug Margins with Covered Entity Characteristics

Area of Science:

• Health Economics
• Pharmaceutical Policy
• Healthcare Management

Background:

• The 340B Drug Pricing Program enables eligible healthcare facilities to purchase outpatient drugs at reduced prices.
• While the program's reach has expanded, its profit margins remain under-examined.
• Understanding factors influencing 340B profit margins is crucial for program integrity and patient access.

Purpose of the Study:

• To investigate drug, facility, and geographic factors affecting profit margins within the 340B Drug Pricing Program.
• To analyze predictors of facility-level 340B margins across different drug classes and healthcare settings.

Main Methods:

• Cross-sectional analysis of 2021 data from linked proprietary and public datasets.
• Multivariable regression modeling to identify predictors of facility-level 340B margins.
• Inclusion of 5 drug classes and examination of drug, facility, and geographic market characteristics.

Main Results:

• 340B drug margins are influenced by drug type, facility characteristics, and healthcare market concentration.
• Hospital outpatient departments and facilities in less competitive markets exhibited higher 340B margins.
• Facility market power and area wealth were positively associated with increased 340B drug margins.

Conclusions:

• 340B program margins are higher in facilities with greater market power and those serving more affluent populations.
• Findings suggest potential shifts in 340B program utilization towards wealthier communities.
• Recommendations for program reform are needed to ensure focus on low-income and uninsured populations.